Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Shelf life: 24 months from the manufacturing date
Obesity and adipose tissue research Type 2 diabetes and insulin resistance Knee osteoarthritis Obstructive sleep apnea Non-alcoholic steatohepatitis (NASH) Key Findings from the Literature 01Phase 2: 24.2% mean weight loss at 48 weeks at highest dose 02Phase 3 TRIUMPH-4: 28.7% mean weight loss at 68 weeks 03Highest weight loss efficacy of any obesity pharmacotherapy in clinical trials to date 04Glucagon receptor agonism adds hepatic lipolysis absent from GLP-1-only agents 1 Independent third-party lab reports for this peptide
Safe and effective for some, not all
At research-level dosages, studies have not reported extensive adverse effects
US$ 26.43
US$ 21.06
US$ 26.12
US$ 24.29
US$ 28.42
US$ 21.89
US$ 25.82
US$ 21.98
